Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing
Thyroid cancer is the most common malignant tumour of the endocrine system. One of the most frequent types of thyroid malignancy is papillary carcinoma. In our study, we performed next generation sequencing (NGS) using a cancer panel (Illumina; Illumina, San Diego, USA) to screen for pharmacogenetic...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-07-01
|
| Series: | Biotechnology & Biotechnological Equipment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/13102818.2017.1335614 |
| _version_ | 1818969436483223552 |
|---|---|
| author | Zora Hammoudeh Dragomira Nikolova Lubomir Balabanski Samuil Ivanov Radoslava Vazharova Sabine Weidner Maxim Malinov Draga Toncheva |
| author_facet | Zora Hammoudeh Dragomira Nikolova Lubomir Balabanski Samuil Ivanov Radoslava Vazharova Sabine Weidner Maxim Malinov Draga Toncheva |
| author_sort | Zora Hammoudeh |
| collection | DOAJ |
| description | Thyroid cancer is the most common malignant tumour of the endocrine system. One of the most frequent types of thyroid malignancy is papillary carcinoma. In our study, we performed next generation sequencing (NGS) using a cancer panel (Illumina; Illumina, San Diego, USA) to screen for pharmacogenetic susceptibility variants in blood samples of 10 patients with papillary thyroid cancer (PTC). We report variants rs1042522 (TP53), rs2228001 (XPC), rs2227983 (EGFR), rs13181 (ERCC2), rs17655 (ERCC5) and rs1799939 (RET), which were detected in the analyzed patients either in homozygous and/or heterozygous state previously known to be connected with pharmacogenetic sensitivity to certain drugs in oncology. The results showed the TruSight Cancer Panel to be a useful clinical tool for determination of oncotherapy-associated pharmacogenetic variants in the blood of patients. |
| first_indexed | 2024-12-20T14:20:33Z |
| format | Article |
| id | doaj.art-c15b0d21b6284a2c82bff71e57e01405 |
| institution | Directory Open Access Journal |
| issn | 1310-2818 1314-3530 |
| language | English |
| last_indexed | 2024-12-20T14:20:33Z |
| publishDate | 2017-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Biotechnology & Biotechnological Equipment |
| spelling | doaj.art-c15b0d21b6284a2c82bff71e57e014052022-12-21T19:37:56ZengTaylor & Francis GroupBiotechnology & Biotechnological Equipment1310-28181314-35302017-07-0131476176510.1080/13102818.2017.13356141335614Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencingZora Hammoudeh0Dragomira Nikolova1Lubomir Balabanski2Samuil Ivanov3Radoslava Vazharova4Sabine Weidner5Maxim Malinov6Draga Toncheva7Medical University of SofiaMedical University of SofiaSBALGAR “Malinov” ClinicSBALGAR “Malinov” ClinicSBALGAR “Malinov” ClinicUniversity Hospital Inselspital BernSBALGAR “Malinov” ClinicMedical University of SofiaThyroid cancer is the most common malignant tumour of the endocrine system. One of the most frequent types of thyroid malignancy is papillary carcinoma. In our study, we performed next generation sequencing (NGS) using a cancer panel (Illumina; Illumina, San Diego, USA) to screen for pharmacogenetic susceptibility variants in blood samples of 10 patients with papillary thyroid cancer (PTC). We report variants rs1042522 (TP53), rs2228001 (XPC), rs2227983 (EGFR), rs13181 (ERCC2), rs17655 (ERCC5) and rs1799939 (RET), which were detected in the analyzed patients either in homozygous and/or heterozygous state previously known to be connected with pharmacogenetic sensitivity to certain drugs in oncology. The results showed the TruSight Cancer Panel to be a useful clinical tool for determination of oncotherapy-associated pharmacogenetic variants in the blood of patients.http://dx.doi.org/10.1080/13102818.2017.1335614Papillary thyroid cancer (PTC)drug sensitivitynext generation sequencing (NGS)pharmacogenetic variants |
| spellingShingle | Zora Hammoudeh Dragomira Nikolova Lubomir Balabanski Samuil Ivanov Radoslava Vazharova Sabine Weidner Maxim Malinov Draga Toncheva Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing Biotechnology & Biotechnological Equipment Papillary thyroid cancer (PTC) drug sensitivity next generation sequencing (NGS) pharmacogenetic variants |
| title | Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing |
| title_full | Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing |
| title_fullStr | Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing |
| title_full_unstemmed | Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing |
| title_short | Screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing |
| title_sort | screening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencing |
| topic | Papillary thyroid cancer (PTC) drug sensitivity next generation sequencing (NGS) pharmacogenetic variants |
| url | http://dx.doi.org/10.1080/13102818.2017.1335614 |
| work_keys_str_mv | AT zorahammoudeh screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing AT dragomiranikolova screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing AT lubomirbalabanski screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing AT samuilivanov screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing AT radoslavavazharova screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing AT sabineweidner screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing AT maximmalinov screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing AT dragatoncheva screeningofpharmacogeneticvariantsassociatedwithdrugsensitivityinpatientswithpapillarythyroidcarcinomausingnextgenerationsequencing |